Generic Name and Formulations:
Varicella zoster vaccine recombinant, adjuvanted; susp for IM inj after reconstitution (contains 50mcg of recombinant glycoprotein E antigen, 50mcg of monophosphoryl lipid A, and 50mcg of QS-21); per 0.5mL; preservative-free.
Indications for SHINGRIX:
Prevention of herpes zoster (shingles) in adults ≥50yrs of age.
Limitations Of use:
Not for preventing primary varicella infection (chickenpox).
<50yrs: not recommended. Give by IM inj in deltoid region of upper arm. ≥50yrs: one 0.5mL dose at Month 0 followed by second dose anytime between 2–6 months later. Administer immediately upon reconstitution or store refrigerated and use within 6hrs.
<18yrs: not established.
Allergies to any previous Shingrix vaccination.
Review immunization history prior to administration. Have appropriate medical treatment and supervision available to manage allergic reactions. Pregnancy. Nursing mothers.
Immunosuppressants may reduce efficacy of Shingrix. Concomitant inactivated influenza vaccines: see full labeling.
Local reactions (eg, pain, redness, swelling), myalgia, fatigue, headache, shivering, fever, GI symptoms.
To report adverse events, contact VAERS at (800) 822-7967.
Single-dose vials—1, 10 (antigen + adjuvant components)
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Smoking Promotes Disease Progression in Multiple Sclerosis
- Situation Framing, Language Can Influence Decision-Making
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products